Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study

Table 3 Changes in Physical Parameters from baseline to 8 weeks in the Placebo and in LI85008F supplemented group

Measure	Study Period	Placebo (x ± SE)	P value^a	LI85008F (x ± SE)	P value^a	P value^b
Body Wt. (Kg)	Baseline	84.97 ± 2.80	< 0.001	86.16 ± 2.75	< 0.001	-
	8 week	83.18 ± 2.82	< 0.001	81.40 ± 2.69	< 0.001	-
	Change	1.79 ± 0.34	-	4.76 ± 0.51	-	< 0.001
Body Mass Index (kg/m²)	Baseline	33.00 ± 0.73	< 0.001	34.41 ± 0.74	< 0.001	-
	8 week	32.30 ± 0.74	< 0.001	32.51 ± 0.75	< 0.001	-
	Change	0.70 ± 0.13	-	1.90 ± 0.19	-	< 0.001
Waist Circumference (cm)	Baseline	108.59 ± 1.99	< 0.001	106.68 ± 1.67	< 0.001	-
	8 week	97.35 ± 2.53	< 0.001	94.16 ± 2.17	< 0.001	-
	Change	11.24 ± 1.95	-	12.52 ± 1.83	-	0.6384
Hip Circum (cm)	Baseline	119.51 ± 1.50	< 0.001	117.99 ± 1.67	< 0.001	-
	8 week	110.68 ± 1.85	< 0.001	108.07 ± 1.65	< 0.001	-
	Change	8.83 ± 0.99	-	9.92 ± 1.34	-	0.0934
Waist-Hip Ratio (WHR)	Baseline	0.91 ± 0.01	<0.05	0.91 ± 0.01	<0.05	-
	8 week	0.88 ± 0.01	<0.05	0.87 ± 0.02	<0.05	-
	Change	0.03 ± 0.01	-	0.04 ± 0.01	-	>0.05
Systolic B.P. (mmHg)	Baseline	120.40 ± 3.40	0.4341	123.33 ± 2.87	0.4094	-
	8 week	118.00 ± 3.04	0.4341	126.19 ± 2.80	0.4094	-
	Change	2.40 ± 2.93	-	−2.86 ± 3.39	-	0.2618
Diastolic B.P. (mmHg)	Baseline	76.20 ± 1.95	0.7388	80.00 ± 2.29	0.5614	-
	8 week	75.50 ± 1.53	0.7388	81.43 ± 2.10	0.5614	-
	Change	0.70 ± 2.02	-	−1.43 ± 2.42	-	0.2146
Heart Rate (Beats/mim)	Baseline	73.20 ± 0.62	0.5953	74.29 ± 0.92	0.6676	-
	8 week	74.00 ± 1.34	0.5953	74.95 ± 0.91	0.6676	-
	Change	−0.80 ± 1.45	-	−0.67 ± 1.53	-	0.4006

^a Difference within the group (baseline vs. final evaluation) using paired t-test.
^b Difference between changes (derived from baseline minus final evaluation) in placebo and LI85008F group using unpaired t-test.